Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery

The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and ankle-related surgeries) in patients undergoing bunionectomy.

  • FX301 combines NaV1.7 inhibitor (funapide) with thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block.
  • The study will start in the first half of this year, with topline data expected in late 2021.
  • The company says that FX301 can potentially provide non-opioid pain relief for at least 3 to 5 days while preserving motor function following musculoskeletal surgery.
  • Preclinical data demonstrated analgesic effect beginning at 1-hour post-dosing compared to placebo and significantly more significant analgesic effect than liposomal bupivacaine at 36 hours post-dosing.
  • Price Action: FLXN shares are 1.4% higher at $11.25 in market trading hours on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralbunionectomyPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!